Tokyo, October 30, 2017 – Nippon Boehringer Ingelheim Co., Ltd. (President and Representative Director: Yoshiaki Aono, “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) announced today that they have agreed to extend the agreement pertaining to the sales of telmisartan (Micardis® family) in Japan to March 31, 2020. The co-promotion agreement will run to March 31, 2018, with no change.
The Micardis® family includes “Micardis® Tablets 20 mg/40 mg/80 mg”, a long-acting angiotensin II receptor antagonist (generic name: telmisartan), “Micamlo® Combination Tablets AP/BP”, a combination drug of telmisartan and the long-acting calcium channel blocker amlodipine besylate, Micombi® Combination Tablets AP/BP, a combination drug of telmisartan and the thiazide diuretic hydrochlorothiazide, and Micatrio® Combination Tablets”, a combination drug of telmisartan, the long-acting calcium channel blocker amlodipine besylate and the thiazide diuretic hydrochlorazide.
The revision of the agreement will have no impact on financial results for the current fiscal year ending March 31, 2018.
Telmisartan, a long-acting angiotensin II receptor antagonist discovered and developed by Boehringer Ingelheim, has been approved in over 100 countries around the world including Japan, USA and EU. In Japan, the Micardis® family is manufactured by Nippon Boehringer Ingelheim, distributed by Astellas, and co-promoted by both companies. In Japan, all these drugs are indicated for hypertension.
Ingelheim Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim(http://www.boehringer-ingelheim.com/) stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned.
As a holding company, Boehringer Ingelheim Japan, Inc. (http://www.boehringer-ingelheim.jp/) manages four business segments under the following companies: Nippon Boehringer Ingelheim Co., Ltd. (prescription medicine), Boehringer Ingelheim Vetmedica Japan and Merial Japan (veterinary medicines), and Boehringer Ingelheim Seiyaku (manufacture of pharmaceutical products).
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.
Contacts for inquiries or additional information:
Nippon Boehringer Ingelheim Co., Ltd.
TEL: +81-3-6417-2145 FAX: +81-3-5435-2920
Astellas Pharma Inc.
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473